<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797468</url>
  </required_header>
  <id_info>
    <org_study_id>HLX23-001</org_study_id>
    <nct_id>NCT04797468</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor</brief_title>
  <official_title>A Phase 1 Clinical Study to Investigate the Safety, Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of HLX23 (CD73 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the CD73 inhibitor HLX23 alone is safe and effective&#xD;
      in participants with advanced solid cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, dose escalation, first-in-human, phase 1 clinical study to investigate the&#xD;
      safety, tolerability and to determine the maximum tolerated dose and recommended phase 2 dose&#xD;
      of HLX23 (recombinant anti-CD73 humanized monoclonal antibody) in patients with advanced or&#xD;
      metastatic solid tumors&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicity</measure>
    <time_frame>Up to 21 Days</time_frame>
    <description>DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum tolerated dose of HLX23</measure>
    <time_frame>Up to 21 Days</time_frame>
    <description>MTD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase 2 dose of HLX23</measure>
    <time_frame>Up to 21 Days</time_frame>
    <description>RP2D</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics(PK)</measure>
    <time_frame>predose, 0,0.5,2,6,24,48,96,168 hours post-dose</time_frame>
    <description>To measure the serum concentration of HLX23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic(PD)</measure>
    <time_frame>predose,2,24,48,96,168 hours post-dose</time_frame>
    <description>Percentage of CD73 receptor occupancy on circulating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>predose at cycle 1, 2, 3, 5, 8, 16, 24, 36, 48 and subsequently every 12 cycles.(each cycle is 1 week)</time_frame>
    <description>Incidence of anti-HLX23 antibody (ADA) positive results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Baseline through Disease Progression or Death (Estimated at up to 2 Years)</time_frame>
    <description>Percentage of Participants with Complete Response (CR) or Partial Response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated at up to 2 Years)</time_frame>
    <description>Percentage of Participants with a Best Overall Response of CR, PR, and Stable Disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>HLX23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HLX23 administered IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX23</intervention_name>
    <description>administered IV.</description>
    <arm_group_label>HLX23</arm_group_label>
    <other_name>CD73 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteer to participate, fully understand the study and have signed the ICF, willing&#xD;
             and have the capacity to comply with and complete all trial procedures;&#xD;
&#xD;
          2. Aged ≥ 18 years when signing the ICF;&#xD;
&#xD;
          3. Patients with advanced or metastatic solid tumors confirmed by histologically or&#xD;
             cytologically, who have failed standard treatment, or who do not have standard&#xD;
             treatment regimens, or who are not suitable for standard treatment;&#xD;
&#xD;
          4. Patients with at least one measurable lesion assessed as per RECIST1.1 criteria;&#xD;
&#xD;
          5. Patients must be able to supply adequate tumor tissue for biomarker (CD73) analyses;&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 when enrolled in the&#xD;
             study;&#xD;
&#xD;
          7. Life expectancy longer than three months;&#xD;
&#xD;
          8. Adequate hematologic functions;&#xD;
&#xD;
          9. Adequate hepatic function ;&#xD;
&#xD;
         10. Adequate renal function, as defined by the creatinine clearance rate ≥ 50 mL/minute by&#xD;
             Cockcroft-Gault formula;&#xD;
&#xD;
         11. Adequate cardiac function ;&#xD;
&#xD;
         12. At least 28 days from prior major surgery or medical device or local radiotherapy, at&#xD;
             least five half-lives from prior cytotoxic chemotherapy, immunotherapy, biological&#xD;
             agents and at least 14 days from prior hormonal therapy and minor surgery before the&#xD;
             first infusion of HLX23;&#xD;
&#xD;
         13. For patients with hepatocellular carcinoma, the Child-Pugh score has to be A;&#xD;
&#xD;
         14. Female participants of childbearing potential and male partners with female partners&#xD;
             of childbearing potential must agree to use one adequate and medically approved&#xD;
             barrier method of contraception during the study and for at least 6 months after the&#xD;
             last dose of the study drugs.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patients who still have ≥ grade 2 toxicities from prior therapies;&#xD;
&#xD;
          2. Patients who have history of allergic reaction to monoclonal antibodies;&#xD;
&#xD;
          3. Concurrent unstable or uncontrolled medical conditions;&#xD;
&#xD;
          4. Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the&#xD;
             cervix (patients with previous history of malignancy but without evidence of disease&#xD;
             for ≥ 3 years can participate in the study);&#xD;
&#xD;
          5. History of prior treatment with anti-CD73 antibodies;&#xD;
&#xD;
          6. Patients with active autoimmune disease, except vitiligo or cured childhood&#xD;
             asthma/allergies that requires no intervention after adulthood, autoimmune-mediated&#xD;
             hypothyroidism treated with stable doses of thyroid hormone replacement, or Type I&#xD;
             diabetes treated with stable doses of insulin can be excepted. Patients in a stable&#xD;
             state and do not require systemic immunosuppressive therapy (including&#xD;
             corticosteroids) are allowed to be enrolled;&#xD;
&#xD;
          7. Pregnancy or breast-feeding;&#xD;
&#xD;
          8. Known history of human immunodeficiency virus infection (HIV), but the patients with&#xD;
             CD4+ T-cell (CD4+) counts ≥ 350 cells/uL are allowed to be enrolled.&#xD;
&#xD;
          9. hepatitis B virus carrier status (HBV surface antigen positive) and hepatitis C&#xD;
             carrier (anti-HCV antibody positive). If HBsAg (+) or HBcAb (+), the&#xD;
             HBV-DNA≥2500copy/mL or 500 IU/mL, or clinically judged active hepatitis; Subjects&#xD;
             co-infected with hepatitis B and hepatitis C should be excluded (positive HBsAg or&#xD;
             HBcAb test and positive HCV antibody test);&#xD;
&#xD;
         10. The patient is the investigator, sub-investigator or anyone directly involved in the&#xD;
             conduct of the study;&#xD;
&#xD;
         11. History or current evidence of any condition or disease that could confound the&#xD;
             results of the study, or participation is not in the best interest of the patient in&#xD;
             the opinion of the Investigator(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

